Should you buy Heron Therapeutics stock now?
No, the technical signal for Heron Therapeutics is currently SELL. Heron Therapeutics trades at $0.00 as of 8/28/2026. The overall technical signal is: Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.040 with falling momentum (signal: -0.040); RSI is at 37.3 (neutral zone). This is a technical observation based on current data, not investment advice.
What is the price target for Heron Therapeutics stock?
There is currently no active analyst price target for Heron Therapeutics.
Is Heron Therapeutics a dividend stock?
No, Heron Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Heron Therapeutics stock?
Heron Therapeutics is rated as a stock in the risk category Extremely speculative. the annual standard deviation is 84.6%, which classifies the stock as Extremely speculative.
Is Heron Therapeutics overvalued?
Heron Therapeutics has the following valuation ratios: a P/S ratio of 0.4, a P/B ratio of 10.5.
Is Heron Therapeutics overbought?
No, Heron Therapeutics is not overbought. RSI is at 37.3 (neutral zone). The technical indicators show: RSI is at 37.3 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, MACD is negative with falling momentum (bearish).
When is the next Heron Therapeutics earnings report?
The date of the next earnings report for Heron Therapeutics has not been published yet. Check the company's investor calendar for updates.
Is Heron Therapeutics shorted?
Yes, Heron Therapeutics is shorted with 31.4% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. Data is updated daily based on official filings with the SEC.
Are insiders buying Heron Therapeutics stock?
No, insiders are not buying Heron Therapeutics shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 8 sales. On a net basis, 48,363 $ worth of shares were sold. Across the last 20 reported transactions, the split is 7 purchases and 13 sales, with a net 9,799,707 $ bought. Active sellers include Hensley Mark Earl, Forbes William P, Duarte Ira and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Heron Therapeutics a good stock?
Based on our total score, Heron Therapeutics is rated as a disastrous stock with a total score of 14 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 30/100, Quality: 10/100, Momentum: 2/100. In addition: technical signal: Sell. Whether Heron Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Heron Therapeutics stock?
The outlook for Heron Therapeutics based on current data: Detailed data is currently not available. Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Heron Therapeutics stock moving?
Heron Therapeutics is moving right now. The technical indicators show: short interest is 31.4% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Heron Therapeutics go?
There is currently no active analyst price target for Heron Therapeutics. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Heron Therapeutics fall?
We lack enough history to give a specific floor for Heron Therapeutics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Heron Therapeutics do?
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic l... The company belongs to the Healthcare sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Heron Therapeutics as an investment.
Did Heron Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Heron Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Heron Therapeutics making money or losing money?
No, Heron Therapeutics is currently not making money — the company is losing money with a negative profit margin of -22.5%, a substantial loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Heron Therapeutics go bankrupt?
The bankruptcy risk of Heron Therapeutics is rated as elevated. Altman Z2 (a model for assessing financial distress) is -22.35 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 2 — which is weak. Debt relative to equity is 1,000% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Heron Therapeutics have a lot of debt?
Yes, Heron Therapeutics has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 1,000%. For the healthcare sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.